In this week’s View, Dr. Eagle discusses the newly published table that lists drug-drug interactions with the anti-viral agent Paxlovid, used in treating COVID-19, then looks at an analysis of the LIFE Trial Run-In that examines the tolerability of sacubitril/valsartan in patients with advanced heart failure. Finally, Dr. Eagle explores the CABANA randomized clinical trial and its insights into the cost-effectiveness of catheter ablation versus antiarrhythmic drug therapy in atrial fibrillation.

Clinical Topics: Anticoagulation Management, Arrhythmias and Clinical EP, COVID-19 Hub, Dyslipidemia, Heart Failure and Cardiomyopathies, Pericardial Disease, Prevention, Valvular Heart Disease, Anticoagulation Management and Atrial Fibrillation, EP Basic Science, SCD/Ventricular Arrhythmias, Atrial Fibrillation/Supraventricular Arrhythmias, Lipid Metabolism, Statins, Acute Heart Failure, Mitral Regurgitation

Keywords: Atrial Fibrillation, Pulmonary Veins, Anti-Arrhythmia Agents, Cost-Benefit Analysis, Ischemic Attack, Transient, Pericardial Effusion, Catheter Ablation, Anticoagulants, Stroke, Cardiomyopathies, Angiotensin Receptor Antagonists, Mitral Valve Insufficiency, Angiotensin-Converting Enzyme Inhibitors, Valsartan, Heart Failure, Enalapril, Angiotensins, Insulins, Ritonavir, Atorvastatin, COVID-19, Pandemics, Drug Interactions, Cytochrome P-450 Enzyme System, Vaccination

< Back to Listings